The theme of this proposal is to both enhance target discovery/confirmation in the projects and to translate such findings regarding potential targets including BH3 proteins/apoptosis machinery, ubiquitin ligases, and key transcription factors. Some or all of these targets will be tested as potentially useful therapeutic strategies by means of early phase clinical trials. Clinical Research Support Core resources are required to carry out these clinical trials and assays on human leukemia cells obtained both at diagnosis/relapse and during the course of therapeutic studies. The personnel in this core will closely interact with the biostatisticians in Core C for trial design, data quality assurance and analysis of results. This Core will be responsible for obtaining required diagnostic and post-treatment samples which will be stored in the tissue bank facility described in Biospecimen Core B after obtaining appropriate consent. Thus the overall Specific Aims of the clinical research support core are to: 1. Collect cells at diagnosis and relapse from patients with AML and higher-risk MDS for storage and annotation in Biospecimen Core B who will perform key biology-defining assays and provide cells to the projects for target development and validation 2. To conduct clinical trials (including obtaining material for ancillary studies) with agents derived from preclinical science in the projects To accomplish these aims we will: * Recruit and enroll eligible patients (including appropriate numbers of individuals across age, gender, ethnicity and racial groups) f o r t h e clinical trials in myeloid leukemias * Coordinate the operation of the clinical trials described in this application. Ensure that study parameters are followed;confirm eligibility for patient registration, treatment program adherence, HIPPA compliance, appropriate dose modification, collection of ancillary data and specimens, adverse event reporting, and toxicity/response assessment * Collect research specimens and distribute ancillary samples via the Biospecimen Core C sample acquisition, storage and distribution mechanism to investigators at the relevant laboratories in the Projects (in some cases straightforward assays may be carried out by Core D shortly after blast isolation if required) * Act as liaison with pharmaceutical companies, outside physicians and hospitals to coordinate the collection of research specimens and follow-up data * Provide central data management for collection and documentation of individual patient information

Public Health Relevance

The research carried out in this project will enable the development of less toxic and more specific therapies for patients with AML and high risk MDS. We plan to rapidly translate laboratory discoveries into useful therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Hanoun, Maher; Zhang, Dachuan; Mizoguchi, Toshihide et al. (2014) Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell 15:365-75
Adamia, Sophia; Bar-Natan, Michal; Haibe-Kains, Benjamin et al. (2014) NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood 123:2816-25
Heckl, Dirk; Kowalczyk, Monika S; Yudovich, David et al. (2014) Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 32:941-6
Adamia, Sophia; Haibe-Kains, Benjamin; Pilarski, Patrick M et al. (2014) A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res 20:1135-45
Bruedigam, Claudia; Bagger, Frederik O; Heidel, Florian H et al. (2014) Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell 15:775-90
Santos, Margarida A; Faryabi, Robert B; Ergen, Aysegul V et al. (2014) DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature 514:107-11
Schneider, Rebekka K; Ademà, Vera; Heckl, Dirk et al. (2014) Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26:509-20
Liu, Suiyang; Yin, Li; Stroopinsky, Dina et al. (2014) MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood 123:734-42
Liss, Adam; Ooi, Chia-Huey; Zjablovskaja, Polina et al. (2014) The gene signature in CCAAT-enhancer-binding protein * dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors. Haematologica 99:697-705
Ng, C E L; Sinha, A; Krivtsov, A et al. (2014) KRas(G12D)-evoked leukemogenesis does not require *-catenin. Leukemia 28:698-702

Showing the most recent 10 out of 218 publications